KIMS Hospitals Announces Q2 FY26 Results
KIMS Hospitals announced Q2 FY26 results with revenue of ₹965Cr, up 23.3% YoY. EBITDA at ₹208Cr, down 6.7% YoY. PAT at ₹72Cr. CMD optimistic about achieving FY26 targets.
The results show revenue growth but a decline in profitability, suggesting a moderate impact on the company's performance.
The announcement provides a mix of positive (revenue growth) and negative (EBITDA and PAT degrowth) financial results, leading to a neutral sentiment.
* KIMS Hospitals announced its Q2 FY26 results on 7th November 2025. * Total Revenue stood at ₹965 crore, a growth of 23.3% YoY and 9.8% QoQ. * EBITDA was ₹208 crore, a degrowth of 6.7% YoY and a growth of 4.3% QoQ. * EBITDA margin at 21.6% compared to 28.5% in Q2 FY25 and 22.7% in Q1 FY26. * PAT stood at ₹72 crore in Q2 FY26 against ₹121 crore and ₹85 crore in Q2 FY25 and Q1 FY26 respectively. * Consolidated EPS for Q2 FY26 was ₹1.67, a degrowth of 37.7% YoY and 14.7% QOQ respectively. * Cash and Cash Equivalents at ₹120 crore as of 30th September 2025. * Consolidated Revenue from Operations of ₹961 crore, a growth of 23.6% YoY and 10.2% QoQ. * Consolidated EBITDA (Pre-INDAS) of ₹201 crore, a degrowth of 8.6% on YoY and a growth of 3.6% on QoQ basis. * ARPOB grew by 9.8% and a de growth of 2.3% on YoY and QoQ basis respectively. * ARPP grew by 7.3% and a de growth of 1.6% on YoY and QoQ basis respectively. * Dr. B Bhaskar Rao, CMD, KIMS Hospitals, mentioned that Q2 FY26 has been a busy quarter with increasing patient footfalls and expressed optimism about achieving targets for the remaining half of FY26.
What to do with a filing like this
Krishna Institute of Medical Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krishna Institute of Medical Sciences Limited. Read the original for the full detail.